- Home
- CRT vs CNTX Comparison
CRT vs CNTX Comparison
Compare CRT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- CNTX
- Stock Information
- Founded
- CRT 1991
- CNTX 2015
- Country
- CRT United States
- CNTX United States
- Employees
- CRT N/A
- CNTX N/A
- Industry
- CRT Oil & Gas Production
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- CNTX Health Care
- Exchange
- CRT Nasdaq
- CNTX Nasdaq
- Market Cap
- CRT 65.1M
- CNTX 78.0M
- IPO Year
- CRT 1992
- CNTX 2021
- Fundamental
- Price
- CRT $9.70
- CNTX $0.64
- Analyst Decision
- CRT
- CNTX Strong Buy
- Analyst Count
- CRT 0
- CNTX 5
- Target Price
- CRT N/A
- CNTX $5.50
- AVG Volume (30 Days)
- CRT 22.2K
- CNTX 312.3K
- Earning Date
- CRT 01-01-0001
- CNTX 08-06-2025
- Dividend Yield
- CRT 9.19%
- CNTX N/A
- EPS Growth
- CRT N/A
- CNTX N/A
- EPS
- CRT 0.99
- CNTX N/A
- Revenue
- CRT $6,834,116.00
- CNTX N/A
- Revenue This Year
- CRT N/A
- CNTX N/A
- Revenue Next Year
- CRT N/A
- CNTX N/A
- P/E Ratio
- CRT $9.81
- CNTX N/A
- Revenue Growth
- CRT N/A
- CNTX N/A
- 52 Week Low
- CRT $8.88
- CNTX $0.49
- 52 Week High
- CRT $13.31
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CRT 41.51
- CNTX 46.34
- Support Level
- CRT $9.74
- CNTX $0.62
- Resistance Level
- CRT $9.99
- CNTX $0.70
- Average True Range (ATR)
- CRT 0.18
- CNTX 0.04
- MACD
- CRT 0.00
- CNTX 0.01
- Stochastic Oscillator
- CRT 8.11
- CNTX 42.86
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.